Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte

NCT ID: NCT05193890

Last Updated: 2022-01-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 69 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-06-01
• Study Completion Date: 2021-05-31

Brief Summary

ABSTRACT

Background and Aims:

To determine the diagnostic performance of the epilepsy and intellectual disability panel used in the pediatric population, starting in June 2019, at the Regional University Hospital Center of Nancy, France.

Design:

An observational and retrospective study, at the Regional University Hospital Center of Nancy, France.

Materials and Methods:

Pediatric patients who underwent genetic analysis with the epilepsy-intellectual disability gene panel. All of these patients were either epileptic or had intellectual disability, or both, of undetermined etiology.

Results:

We included 69 patients in this study. We identified causative mutations in 46.4% (32 of 69 patients) of this cohort after the gene panel and 52.2% (36 patients) including positive results after realization of the Clinical Exome Solution.

Detailed Description

Epilepsy and intellectual disability are common and highly heterogeneous neurodevelopmental disorders in children. Their respective prevalence are 3.2 to 5.1/1000 (1,2) and 1.3 to 2.2% (3).

An epileptic seizure is due to abnormal excessive or synchronous neuronal activity. Epilepsy is defined by : (A) At least two unprovoked (or reflex) seizures occurring >24 h apart; or (B) one unprovoked (or reflex) seizure and a probability of further seizures at least 60% ; or (C) diagnosis of an epilepsy syndrome (4). Intellectual disability (ID) is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as a significant limitation in intellectual functioning and adaptive behavior, which include conceptual, social, and practical skills, arising before age 18.

These two conditions can be caused by a variety of environmental and genetic factors, often combined, making the diagnosis difficult (5,6). Standard diagnostic approaches include biochemical and enzyme analysis for neurometabolic disorders, MRI brain imaging and genome-wide microarray analysis (7-9).

Because of the large variability of genotypic-phenotypic expression (a syndrome can have several genetic causes; the same gene can be expressed in different ways) and the huge genetic heterogeneity, the identification of the genes involved in these pathologies has long been difficult. In recent decades, considerable progress has been made in genetics, with the development of new technologies such as next-generation sequencing (NGS). These new techniques permit the sequencing of many genes at the same time, at an ever lower cost, allowing the use of these tests in clinical practice routine with gene panels, and even whole-exome or whole-genome sequencing (10). We now identified more than 1000 genes implicated in mechanisms of epilepsy and ID, with various pathways (11-16).

Conditions

Epilepsy; Intellectual Disability

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Epilepsy only

Epilepsy only patients who underwent our gene panel and the Clinical exome Solution

retrospective analysis of a panel result

Intervention Type: GENETIC

retrospective analysis of a exome clinical solution

Intelectual Disability only

Intelectual Disability only patients who underwent our gene panel and the Clinical exome Solution

retrospective analysis of a panel result

Intervention Type: GENETIC

retrospective analysis of a exome clinical solution

Epilepsy and Intelectual Disability

Intelectual Disability and Epilepsy patients who underwent our gene panel and the Clinical exome Solution

retrospective analysis of a panel result

Intervention Type: GENETIC

retrospective analysis of a exome clinical solution

Interventions

retrospective analysis of a panel result

retrospective analysis of a exome clinical solution

Intervention Type: GENETIC

Eligibility Criteria

Inclusion Criteria

• We included in our study all pediatric patients who underwent genetic analysis with the epilepsy-intellectual disability gene panel between June 2019 and May 2021. All of these patients were either epileptic or had intellectual disability, or both, of undetermined or genetic presumed etiology.

Exclusion Criteria

• We excluded i) patients older than 18 years, ii) those for whom the indication for genetic analysis was not epilepsy or intellectual disability iii) patients not followed up at the Regional University Hospital Center of Nancy, France.

• Minimum Eligible Age: 1 Day
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

calina TODOSI

MD, Pediatric Neurology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Calina Todosi

Vandœuvre-lès-Nancy, , France

Countries

France

Other Identifiers

2021PI127.

Identifier Type: -

Identifier Source: org_study_id